Las Vegas, USA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Propulsion of Malignant Mesothelioma Pipeline as Novel and Extensive Therapies Enter the Treatment Domain, Anticipates...
Sanofi Canada (SNY) announces that Health Canada has approved SARCLISA in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult patients with relapsed...
Sanofi’s (SNY) tolebrutinib demonstrated favorable one-year tolerability in a Phase 2b long-term extension study ((LTS)) in patients with relapsing forms of multiple sclerosis...
Pfizer Submits Vaccine Trial Data For Kids As Young As 5; Sanofi Abandons Development Of mRNA JabYesterday while receiving his Pfizer booster jab during a live-streamed media...
France's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock...
Sanofi has entered into a definitive agreement with Translate Bio for $38.00 per share in cash, which represents a total equity value of $3.2B a fully diluted basis.
Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | Buy | Neutral | Buy |
| Technical Indicators | Strong Buy | Strong Sell | Buy |
| Summary | Strong Buy | Sell | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 49.12 | 49.23 | 47.97 | +0.68 | +1.39% | 209.04M | London | |||
| 110.44 | 111.28 | 109.64 | -0.68 | -0.61% | 59.55M | London | |||
| 332.60 | 332.70 | 319.10 | +10.70 | +3.32% | 1.64M | London | |||
| 52.04 | 55.18 | 51.64 | +0.22 | +0.42% | 13.35M | London | |||
| 92.60 | 93.55 | 91.05 | +1.55 | +1.70% | 2.20M | London | |||
| 1,818.00 | 1,822.00 | 1,786.50 | +18.00 | +1.00% | 260.29K | London | |||
| 267.90 | 269.60 | 265.90 | +1.90 | +0.71% | 12.48M | London | |||
| 1,076.00 | 1,080.00 | 1,066.00 | +6.00 | +0.56% | 230.09K | London | |||
| 65.30 | 66.20 | 64.70 | +0.60 | +0.93% | 1.60M | London | |||
| 434.20 | 436.05 | 430.70 | +8.20 | +1.93% | 36.06M | London | |||
| 184.20 | 185.85 | 182.05 | +0.85 | +0.46% | 4.62M | London | |||
| 5.49 | 5.50 | 5.49 | 0.00 | 0.00% | 0.00 | London | |||
| 18.00 | 18.30 | 18.00 | +0.100 | +0.56% | 18.94M | London | |||
| 2,010.00 | 2,035.00 | 2,010.00 | +5.00 | +0.25% | 36.85K | London | |||
| 110.50 | 110.50 | 110.50 | 0.00 | 0.00% | 0.00 | London |
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.